Medical Management of Melanoma

  • Author: Ahmad Tarhini, MD, PhD (More Info)
  • Associate Editor: John M. Kirkwood, MD
  • Editor In Chief: Ramaswamy Govindan, MD
  • Last Reviewed: 7/26/18 (What's New)

Summary

  • The combination of encorafenib, a BRAF inhibitor, plus binimetinib, a MEK kinase inhibitor, FDA approved for unresectable or metastatic melanoma with a BRAF V600E or V600K mutation
    • PFS: 14.9 months (95% CI: 11.0-18.5) with combination compared with 9.6 months (95% CI: 7.5-14.8) with encorafenib alone or 7.3 months (95% CI: 5.6-8.2) with vemurafenib alone[Dummer 2018]
    • Adverse events include gastrointestinal toxicities (diarrhea, nausea, vomiting), fatigue, and arthralgia[Dummer 2018]

Action required